1.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1230.4, 2008-003617-27, NCT00804856
|
|
2.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1230.5, NCT00824408
|
|
3.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1230.2, NCT01023958
|
|
4.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1230.18, 2009-015770-35, NCT01121406
|
|
5.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1230.16, NCT00969553
|
|
6.
|
Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1230.6, 2008-003926-40, NCT00969761
|
|
7.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1230.7, 2008-008304-41, NCT01022853
|
|
8.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: 1230.23, 2009-018199-32, NCT01145885
|
|
9.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1230.20, 2010-019437-97, NCT01206816
|
|
10.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1230.15, NCT01348347
|